Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT05360537

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05360537
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05360537. Randomized; double masking; primary purpose treatment. Start 2021-04-01 (actual); primary completion 2021-12-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin Degludec / Liraglutide Injectable Product
Intervention (Drug)
Insulin Glargine
Lead sponsor
University of Palermo (class: other)

Record details

Record id
cardio:ct-nct05360537
Content hash
ffac486444c2f9f60f9e52613461fc10aaf93b5d344d363abf073da29a74d3df